The prevalence of EGFR mutations in non‐small cell lung cancer in an unselected Caucasian population
- 25 November 2014
- Vol. 123 (2), 108-115
- https://doi.org/10.1111/apm.12328
Abstract
EGFR mutation frequencies in unselected Caucasian populations are unknown. This study assesses the prevalence of EGFR mutations in an unselected population-based cohort, and the correlation between mutation and gender, age, ethnicity, smoking habits, and pathological data. NSCLC patients diagnosed in a well-defined Danish population were included. The type of the diagnostic material, and data on smoking were registered. The mutation analyses were investigated by Therascreen EGFR RGQ-PCR Kit or Sanger sequencing. A total of 658 men and 598 women were included. 6.2% were never smokers, 38.9% were ex-smokers, and 54.9% were current smokers. One thousand one hundred and sixty-one (92.4%) patients had sufficient material for mutation analysis. Cytological material was used for 38% of the mutation analyses. 5.4% had mutation in the EGFR gene (4.3% men/6.7% women). 87% were activating mutations. 8.0% of adenocarcinomas, and 1.9% of squamous cell carcinomas were mutated. 29.4%, 4.4% and 2.9% of never, ex- and current smokers were mutated (p < 0.001). No difference in mutation rate was observed between patients with cytology only, histology only or both cytology and histology available. 5.4% of the patients had EGFR mutation. Adenocarcinomas were mutated more often (8.0%) than squamous cell carcinomas (1.9%). Mutations were found in never smokers as well as in former and current smokers. No difference in gender and age regarding mutation status was observed. EGFR mutations analysis was possible in almost all patients with no difference between cytology and histology specimens.Keywords
This publication has 38 references indexed in Scilit:
- The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort studyBMJ Open, 2013
- Comparison of molecular testing methods for the detection ofEGFRmutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancerJournal of Clinical Pathology, 2013
- EGFRmutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samplesJournal of Clinical Pathology, 2012
- Response to Erlotinib in Patients with EGFR Mutant Advanced Non–Small Cell Lung Cancers with a Squamous or Squamous-like ComponentMolecular Cancer Therapeutics, 2012
- Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic OpportunitiesClinical Cancer Research, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 MutationsClinical Cancer Research, 2012
- Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNature Reviews Cancer, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeThe New England Journal of Medicine, 2005